

VALEANT PHARMACEUTICALS INTERNATIONAL  
Form 8-K  
September 22, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): September 22, 2010 (September 22, 2010)**

**VALEANT PHARMACEUTICALS INTERNATIONAL**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**1-11397**  
(Commission File Number)

**33-0628076**  
(IRS Employer Identification  
Number)

**One Enterprise**  
**Aliso Viejo, California 92656**  
(Address of principal executive offices, including zip code)  
**(949) 461-6000**  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On September 22, 2010, Valeant Pharmaceuticals International, a Delaware corporation ( Valeant ), issued a press release announcing the pricing of \$500 million aggregate principal amount of its 6.75% Senior Notes due 2017 and \$700 million aggregate principal amount of its 7.00% Senior Notes due 2020. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

**Exhibit**

**Number Description of Exhibit**

99.1 Press Release dated September 22, 2010.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL,

by /s/ Peter J. Blott

Name: Peter J. Blott  
Title: Executive Vice President and Chief  
Financial Officer

Date: September 22, 2010

---

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release dated September 22, 2010.